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Abstract
Defensins are effectors of the innate immune response with potent antibacterial activity. Their role in antiviral immunity,
particularly for non-enveloped viruses, is poorly understood. We recently found that human alpha-defensins inhibit human
adenovirus (HAdV) by preventing virus uncoating and release of the endosomalytic protein VI during cell entry. Consequently,
AdV remains trapped in the endosomal/lysosomal pathway rather than trafficking to the nucleus. To gain insight into the
mechanism of defensin-mediated neutralization, we analyzed the specificity of the AdV-defensin interaction. Sensitivity to alpha-
defensinneutralization isacommonfeatureofHAdVspeciesA,B1,B2,C,andE,whereasspeciesD andFareresistant.Thousands
of defensin molecules bind with low micromolar affinity to a sensitive serotype, but only a low level of binding is observed to
resistant serotypes. Neutralization is dependent upon a correctly folded defensin molecule, suggesting that specific molecular
interactions occur with the virion. CryoEM structural studies and protein sequenceanalysis led to a hypothesis that neutralization
determinants are located in a region spanning the fiber and penton base proteins. This model was supported by infectivity
studies using virus chimeras comprised of capsid proteins from sensitive and resistant serotypes. These findings suggest a
mechanism in which defensin binding tocriticalsites on the AdVcapsid preventsvertex removaland thereby blocks subsequent
steps in uncoating that are required for release of protein VI and endosomalysis during infection. In addition to informing the
mechanism of defensin-mediated neutralization of a non-enveloped virus, these studies provide insight into the mechanism of
AdV uncoating and suggest new strategies to disrupt this process and inhibit infection.
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Introduction
Defensins are an evolutionarily conserved family of antimicro-
bial peptides that are an important effector component of the
innate immune response. Humans express two classes of defensins,
a- and b-defensins. There are six human a-defensins (HNP1–4,
HD5, and HD6) and multiple b-defensins, which differ in their
tissue distribution and expression patterns [1,2]. Both a- and b-
defensins are small peptides with three intramolecular disulfide
bonds and are potent antibacterial agents. There is substantial
evidence that a major bactericidal mechanism of defensins is
through membrane disruption [3], and lipid bilayer interactions
are facilitated by their amphipathicity and net positive charge. A
growing body of evidence suggests that certain defensins are also
potent antivirals. For enveloped viruses, direct disruption of the
viral lipid envelope bilayer has been proposed as a mechanism for
neutralization [4]. In addition, several defensins have been shown
to be lectins and to block human immunodeficiency virus and
Herpes simplex virus binding to cellular receptors [5–7].
Defensins have also been shown to neutralize several non-
enveloped viruses, including human adenovirus (HAdV), human
papillomavirus (HPV), adeno-associated virus (AAV), and poly-
omavirus, despite the absence of a lipid target [8–14]. We have
chosen HAdV as a tractable model system to analyze this process
at the molecular level. AdV is a dsDNA virus with an icosahedral
capsid composed primarily of 240 trimers of hexon. Each of the
twelve icosahedral vertices contains a penton complex comprised
of the non-covalently associated fiber and penton base proteins.
The capsid is stabilized by proteins IIIa, VI, VIII, and IX. There
are 52 serotypes of HAdV divided into 7 species, A–G [15,16].
Three additional types (HAdV-53, -54, and -55) have also recently
been described [17,18]. The mode of cell entry is best understood
for the HAdV-C serotypes in cultured epithelial cells and is
initiated by a high affinity interaction between the distal knob of
the fiber and one of several cell surface receptors [19].
Internalization via clathrin-mediated endocytosis is triggered by
the interaction between an RGD motif in penton base and cellular
integrin co-receptors [20]. Uncoating, which is the removal of the
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fashion beginning with dissociation of the fiber from the capsid at
or near the cell surface [21,22]. Additional uncoating events,
including release of the endosomalytic protein VI, occur in the
endosome in response to cellular triggers such as acidification [23].
Upon escape from the early endosome, the partially uncoated
capsid travels along microtubules and docks at the nuclear pore
complex, where the viral genome enters the nucleus [24].
Our previous studies revealed the stage in the virus entry pathway
that is blocked by defensins [13]. We found that the a-defensins
HNP1 and HD5 significantly inhibit HAdV-5 infection at low
micromolar concentrations. Although receptor binding and virus
internalization were unaffected, virus escape from the endosome was
blocked. Moreover, defensin binding stabilized the virus capsid in
thermal denaturation assays. These observations are consistent with a
mechanism by which defensins neutralize AdV infection by blocking
uncoating and release of the endosomalytic proteinVI. Wehave now
extended these studies to determine the specificity of defensin binding
to HAdV, to approximate the stoichiometry and affinity of this
interaction, and to identify the neutralization determinants on the
virus capsid. These studies not only contribute to an understanding of
the mechanism of defensin-mediated neutralization of non-enveloped
virus infection but also provide insight into the process of HAdV
uncoating during infection.
Results
Sensitivity of HAdV to defensins is species specific
In our previous studies we showed that a small subset of HAdVs,
including HAdV-5, -12, and -35 (species C, A, and B2, respectively)
are neutralized by a-defensins [13]; however, the underlying
molecular mechanisms were not delineated. To determine whether
sensitivity to a-defensins is a general property of HAdVs, serotypes
representativeofHAdV speciesA–Fweretested forinfectivityinthe
presence of 15 mM HD5 or HNP1 (Figure 1). Wild type HAdVs
rather than vectors were used for these studies, and infectivity was
assessed by staining for hexon production. We found that each of
HAdV types belonging to species A, B1, B2, C, and E is sensitive to
HD5. Strikingly, the HAdV-D and F serotypes are completely
resistant to HD5-mediated neutralization and, in most cases,
infection is actually enhanced. Serotypes sensitive to HD5 are also
generally sensitive to HNP1, although only modest inhibition was
observed forHAdVs-3, -12, -14, and-16.One exceptionis HAdV-4
(species E), which is moderately sensitive to HD5 but resistant to
HNP1. None of the tested serotypes is sensitive to the b-defensin
HBD2 (data not shown). These studies indicate that sensitivity to a-
defensins is species specific. In addition, particular HAdV serotypes
are not equally sensitive to all defensins, indicating defensin
sequence specificity as well.
HAdV neutralization correlates with defensin binding to
the capsid
Neutralization of HAdV by a-defensins is dependent upon
binding to the virus capsid, which can be disrupted in the presence
Author Summary
Defensins are effectors of the innate immune response
with antibacterial and antiviral activity. A major bacteri-
cidal mechanism of defensins is membrane disruption;
however, their mechanism against non-enveloped viruses,
such as human adenovirus, is poorly understood. This work
shows that sensitivity of human adenovirus to defensins is
species specific and that neutralization is dependent upon
defensin tertiary structure. A cryoEM structural study of an
adenovirus vector in complex with a neutralizing defensin,
HD5, led to a neutralization model in which defensin binds
to the interface of two capsid proteins, preventing
dissociation of the fiber protein. We propose that binding
at this site blocks downstream uncoating events required
for infection. Infectivity studies using virus chimeras
comprised of capsid proteins from sensitive and resistant
human adenovirus serotypes support this model. This
functional and structural study provides insight into the
mechanism of human adenovirus neutralization by defen-
sins and suggests new strategies to inhibit infection.
Figure 1. Sensitivity to neutralization by alpha-defensins is AdV species specific. HAdVs were incubated with 15 mM HD5 (A) or HNP1 (B)
and assessed for infectivity on A549 cells. Data are the mean of the percent infectivity compared to control cells infected with each virus in the
absence of defensin for at least three independent experiments 6 SD. The upper limit for quantification of this assay is 200%. Virus serotypes are
grouped by species (A–F).
doi:10.1371/journal.ppat.1000959.g001
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more quantitative assessment of this interaction, increasing
concentrations of HD5 were incubated with Ad5.eGFP to allow
binding, and the virus/HD5 complex was then separated from
unbound HD5 on a nycodenz gradient. Bound defensin was
visualized after SDS-PAGE using a sensitive fluorescent total
protein stain and quantified against a standard curve. These
experiments showed that defensin binding to the HAdV-5 capsid is
saturable, suggesting specificity, and that at saturation approxi-
mately 2750 HD5 molecules are bound to each virus particle (95%
confidence interval=1603–3919 HD5 molecules) (Figure 2A). In
addition, the KD of this interaction is approximately 14.5 mM (95%
confidence interval=2.8–26.2 mM), which correlates reasonably
well with the IC50 of HD5 for HAdV-5 infection (3–4 mM) [13].
We assessed HD5 binding to additional serotypes after
incubation with 20 mM HD5 (Figure 2B). The sensitive serotype
HAdV-7p bound 69.3615.9% of the amount of HD5 bound to
HAdV-5 in parallel samples; whereas, the corresponding values for
the resistant serotypes HAdV-19c, -25p, and -51p were
32.567.5%, 3.365.8%, and 24.6612.0%, respectively. These
studies demonstrate reduced binding of HD5 to resistant
serotypes, suggesting that binding of a-defensins to species-specific
features on the HAdV capsid correlates with neutralization.
Neutralization by HD5 is dependent upon defensin
tertiary structure
To gain further insight into the defensin-HAdV interaction, we
assessed the requirement for two conserved structural elements on
the anti-AdV activity of HD5. All defensins have three disulfide
bonds (Figure 3A). In addition, all a-defensins possess a conserved
salt bridge, such as that comprised of glutamic acid 14 (E14) and
arginine 6 (R6) in HD5, which has been shown to increase
defensin protease resistance [25,26]. The antibacterial properties
of defensins, which are dependent upon protein-lipid interactions,
are not uniformly conformation dependent [27–29]. In some
cases, incorrectly folded analogs are more potent antibacterial
agents than the correctly folded defensin molecule. In contrast,
defensin-related chemokine activity, which relies on protein-
protein interactions, is dependent on defensin conformation
[28]. We hypothesized that the defensin-capsid interaction for
sensitive serotypes would likely be dependent upon defensin
conformation, as this would be more typical for protein-protein
interactions. To test this hypothesis, HD5 derivatives in which the
six cysteines were replaced with L-a-aminobutyric acid (HD5-
Abu), to prevent the formation of disulfide bonds, or containing a
substitution of glutamine for glutamic acid 14 (HD5-E14Q), to
disrupt the conserved salt bridge, were tested for their activity
against Ad5.eGFP (Figure 3B). Disruption of the R6-E14 salt
bridge had no effect on antiviral activity. In contrast, HD5-Abu
failed to inhibit Ad5.eGFP infection, and no detectable binding of
HD5-Abu was observed upon incubation at 20 mM with HAdV-5
(data not shown). Therefore, HAdV neutralization does not
merely require an amphipathic molecule with a net positive
charge. Rather, specific interactions mediated by the correctly
folded a-defensin molecule are required.
Binding of HD5 to HAdV-5 does not block receptor
interaction
Previously we observed that HD5 enhances binding of HAdV-5
to cells despite an almost complete block to productive infection
[13]. In order to determine the receptor-dependence of this effect,
we pre-incubated cells with recombinant fiber knob from HAdV-5
(5FK) to block receptor (CAR) interactions and measured cell
binding of fluorescently labeled HAdV-5 that was pre-incubated
with or without HD5 or HD5-Abu (Figure 3C). Cells incubated
with fiber knob from HAdV-16 (16FK), which binds CD46, served
as a control. We observed that virus binding to cells was reduced
5.2-fold in the presence of 5FK compared to 16FK. This confirms
the receptor-dependence of the normal interaction of HAdV-5
with cells. Pre-incubation with HD5 increased virus binding to
cells. In this case the presence of 5FK reduced binding 1.6-fold
compared to 16FK, indicating some receptor-dependence of the
virus/cell interaction even in the presence of HD5. Virus pre-
incubated with HD5-Abu was equivalent to virus alone, consistent
Figure 2. HD5 binding to HAdV. A) HD5 binding to a representative defensin-sensitive serotype (HAdV-5) was quantified by an equilibrium-
binding assay. Data are the mean of the number of HD5 molecules bound per virion at the indicated HD5 concentrations from at least three
independent experiments 6 SD. Binding curves were fitted using Prism software. B) Binding of HD5 to additional defensin-sensitive (HAdV-7p) and
resistant (HAdV-19c, -25p, -51p) serotypes expressed as a percent of HD5 bound to HAdV-5. Data are the mean of two or three independent
experiments 6 SD.
doi:10.1371/journal.ppat.1000959.g002
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confirm that HD5 binding to HAdV-5 does not completely block
the interaction with CAR receptor.
CryoEM structural analysis of a HAdV-HD5 complex
To obtain structural insight into the mechanism of a-defensin-
mediated neutralization of HAdV infection, we studied a complex
of Ad5.F35 (Ad35F) and HD5 by cryoelectron microscopy
(cryoEM). This chimeric virus construct was chosen because of
its short fiber and the availability of a cryoEM structure of
Ad5.F35 in the absence of defensin for comparison [30,31]. The
sensitivity of Ad5.F35 to HD5 is comparable to that of HAdV-5
and HAdV-35 (data not shown). Ad5.F35 was incubated with a
saturating concentration of HD5 (20 mM) then applied to grids
and flash frozen for cryoEM. A dataset of 2,611 cryoEM particle
images of the Ad5.F35+HD5 complex was collected and processed
as performed earlier for Ad5.F35 [31]. The resolution of the
icosahedral portion of the Ad5.F35+HD5 reconstruction is
estimated as 12 A ˚ by the FSC 0.5 threshold criterion, compared
to 6.9 A ˚ for the Ad5.F35 reconstruction. Both cryoEM structures
are shown filtered to 12 A ˚ resolution in Figure 4A. The most
noticeable difference between the two structures is the presence of
more density on top of penton base and around the fiber shaft in
the Ad5.F35+HD5 structure. In addition, while the fiber knob is
visible in the Ad5.F35 structure, it is only weakly reconstructed in
the Ad5.F35+HD5 structure (Figure 4A inset).
In order to identify the binding regions for HD5 on the surface
of Ad5.F35, we performed a difference map analysis using the
available crystal structure of the HAdV-5 hexon (PDB 1P30) [32]
and the co-crystal structure of HAdV-2 penton base bound to a
peptide derived from the N-terminus of fiber (PDB 1X9T) [33].
Difference mapping with the crystal structures was preferable to
direct subtraction of the Ad5.F35 structure from the
Ad5.F35+HD5 structure because of ringing in the cryoEM density
maps due to incomplete correction for the contrast transfer
function of the microscope. There are multiple flexible loops with
a total of 51 residues per monomer at the top of hexon (hexon
towers) that are missing from the crystal structure. Density for
these loops (yellow) is clearly visible in the Ad5.F35 difference map
and nearly identical for each of the four unique hexons within the
icosahedral asymmetric unit (Figure 4B, left panel). The
Ad5.F35+HD5 difference map shows density (red) on the hexon
towers that is attributable to both HD5 and the missing hexon
loops (Figure 4B, middle and right panels). This density is variable
for each unique hexon and greatest above the peripentonal hexon
(position 1). The variability in the Ad5.F35+HD5 difference map
suggests that HD5 interacts with and induces additional
conformational heterogeneity in the flexible loops of hexon.
HD5 difference density is also found within the central depression
of the hexon trimers in the same location identified for binding of
Factor X [34,35]. This central depression contains multiple
negatively charged residues that are likely to form a binding site
for the positively charged HD5 molecule.
The difference map analysis reveals multiple binding sites for
HD5 on the penton complex (penton base and fiber). The
Ad5.F35 difference map clearly reveals the flexible RGD loop of
penton base (78 residues) as well as the shaft and knob of fiber
(yellow), which are missing from the penton base/fiber peptide co-
crystal structure (Figure 4C, left panel). The Ad5.F35+HD5
difference map shows significant additional density attributable to
HD5 (red) on top of the penton base and around the fiber shaft
(Figure 4C, middle and right panels). The conformation of the
flexible RGD loop of penton base appears to be perturbed in the
presence of HD5. The position of the fiber knob relative to the
fiber shaft also seems to be modified such that the knob is no
longer reconstructed.
Model for HD5 neutralization of HAdV
The cryoEM analysis of the Ad5.F35+HD5 complex indicates
that HD5 interacts with the exposed surfaces of the three major
capsid proteins: hexon, penton base, and fiber. Previously, we
observed that HD5 does not prevent HAdV-5 from entering host
cells [13,36]. In addition, we observed that HD5 binding stabilizes
the capsid and prevents dissociation of capsid proteins, including
fiber, upon exposure to heat. Therefore, we considered which of
the multiple binding sites visualized by cryoEM might lead to
Figure 3. HD5 antiviral activity is structure dependent. A) Ribbon representation of HD5 (PDB 1ZMP). Three disulfide bonds are numbered,
and the two residues comprising the conserved salt bridge (R6 and E14) are indicated. B) Ad5.eGFP was incubated with 15 mM of each of the
indicated defensins. HD5-Abu is HD5 with the six cysteines replaced with L-a-aminobutyric acid. Data are the mean percent of eGFP positive cells
compared to control cells infected in the absence of defensin for at least three independent experiments 6 SD. C) Binding of Alexa Fluor 488-labeled
HAdV-5 to cells was assessed after incubation with or without 20 mM HD5 or HD5-Abu and in competition with 100 nM 5FK or 16 FK. Data are the
mean fold increase in geometric mean fluorescence compared to cells alone and are of at least 10,000 cells from each of three independent
experiments 6 SD.
doi:10.1371/journal.ppat.1000959.g003
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coded (blue=405 A ˚; cyan=425 A ˚; green=445 A ˚, yellow=465 A ˚; red=485 A ˚). Inset, enlarged views of the vertex regions. B) and C) Ad5.F35 and
Ad5.F35+HD5 difference maps. The density representations of the docked hexon and penton base/fiber complex are in blue, the Ad5.F35 difference
map is in yellow, and the Ad5.F35+HD5 difference map is in red. Two threshold levels are shown for the Ad5.F35+HD5 difference map, one showing
only the strongest density (middle) and a second at just above the noise level (right). Only one threshold level is shown for the Ad5.F35 difference
map at just above the noise level. B) Four unique hexons, numbered 1–4, within the asymmetric unit of the icosahedral capsid. C) Penton base and
fiber viewed at a 45u angle. Scale bars, 100A ˚.
doi:10.1371/journal.ppat.1000959.g004
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negatively charged region of the capsid that was present within the
protein sequences of sensitive serotypes and not present in resistant
serotypes and that was also in the vicinity of HD5 cryoEM
difference density. In particular, we were looking for a possible
binding site for HD5 that might bridge adjacent capsid subunits
and stabilize the capsid. By comparing the N-terminal sequences
of fibers from HAdV types that are either sensitive or resistant to
HD5 we identified one negatively charged region that is present in
all of the sensitive serotypes (i.e., 18-DTET-21 in HAdV-5; DPFD
in HAdV-12; EDES in HAdV-3; DADN in HAdV-4) (Figure 5A).
In resistant serotypes of species D the corresponding region of the
fiber is non-polar and positively charged (i.e., 18-GYAR-21 in
HAdV-19c). Serotype HAdV-41 is resistant to HD5, despite
having a single negatively charged residue in this region; however,
it is different from all of the other serotypes we examined in that it
has both a short and a long fiber, which could affect the
mechanism of HD5 neutralization. The variable fiber region,
Figure 5. HD5 binding regions on the penton base and fiber. (A) Alignment of the N-terminal sequences of fiber from serotypes that were
studied for defensin sensitivity. Several sequences are representative of multiple serotypes within a species, as indicated. HAdV-F serotypes havea
short (S) and long (L) fiber. No sequence information is available for this region for HAdV-23 and -51. Sequences for defensin-resistant serotypes arei n
red and those for defensin-sensitive serotypes are in black. The variable region is in bold with the key residues underlined for HAdV-C and HAdV-D.
Sequences shown correspond to residues 10 to 35 in HAdV-2. B-D) The strongest density in the Ad5.F35+HD5 difference map (black mesh) is shown
together with the Ad5.F35 difference map (colored in gold for the RGD loop of the penton base and green for the fiber shaft). Also shown are the
docked penton base (gold ribbon) and N-terminal fiber peptide (green ribbon) from the HAdV-2 penton crystal structure (PDB 1X9T). The side chains
of fiber residues Asp-18 and Thr-19 (DT of DTET) are shown in a space filling representation. The penton complex is shown in both top (B) and side (C)
views. In (D), the crystal structure of an HD5 monomer (PDB 1ZMP, blue ribbon) is included for scale.
doi:10.1371/journal.ppat.1000959.g005
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precedes the fiber shaft repeats and directly follows a conserved
motif (FNPVYPY) that binds at the interface of adjacent penton
base monomers [33]. The difference density analysis of
Ad5.F35+HD5 (Figure 5B and C) suggests a possible explanation
for fiber stabilization by HD5, as strong difference density (mesh)
appears to cover the variable fiber sequence (EDES in HAdV-35
or DTET in HAdV-2, partially shown in space filling represen-
tation), effectively pinning the N-terminus of fiber (green ribbon)
against penton base (gold ribbon). Therefore, this variable region
of the fiber may form part of a critical binding site for HD5
neutralization of HAdV. We propose a model for HD5
neutralization of HAdV-5 in which HD5 binds to the interface
of penton base and fiber and prevents fiber dissociation,
consequently blocking downstream uncoating events that are
required for infection.
Fiber and penton base proteins contain critical
neutralization determinants
The availability of sensitive (e.g., HAdV-5) and resistant (e.g.,
HAdV-19c) serotypes provided a means to test this HD5
neutralization model by generating virus chimeras. Initially, virus
chimeras were constructed by replacing the sequences for fiber,
penton base, and hexon in the HAdV-5 genome with the
corresponding sequences from HAdV-19c. Consistent with
previous studies [37,38], the virus chimera containing the
HAdV-19c hexon is not viable; however, constructs containing
the HAdV-19c fiber (19cF) or penton base (19cPB) are capable of
replicating. When each of these viruses was tested for sensitivity to
HD5, we found that the 19cF virus is completely resistant to
neutralization (Figure 6). In contrast, the 19cPB virus has an
intermediate phenotype. It is partially neutralized by HD5 but
only at the higher concentration tested (10 mM). Together, these
results indicate that both fiber and penton base are involved in
HD5 neutralization.
Based on these results, we created an additional construct in
which only the four residues in the HAdV-5 fiber variable region
(DTET) were replaced by the corresponding residues from HAdV-
19c (GYAR). Compared to HAdV-5, the GYAR virus is less
sensitive to 5 mM HD5. We then combined the GYAR
substitution with the PB substitution in a single construct (PB/
GYAR). This construct, like 19cF and wild type HAdV-19c, is
completely resistant to neutralization by HD5. This result confirms
a role for the DTET/GYAR variable fiber region in HD5
neutralization, as the PB/GYAR chimera is even more resistant to
HD5 then 19cPB alone. Additional studies using a higher
concentration of HD5 (20 mM) confirmed the defensin-resistance
of HAdV-19c, 19cF, and PB/GYAR (data not shown). Equivalent
results were obtained using a FACS-based assay that requires 100-
fold lower moi, indicating that variations in particle to pfu ratios
among the virus preparations could not account for the differences
in phenotype (data not shown). Studies equivalent to those in
Figure 2B to measure HD5 binding to both 19cF and PB/GYAR
did not detect a reduction in the amount of HD5 bound to these
viruses compared to HAdV-5 (data not shown). Taken together,
these studies demonstrate that HD5-mediated inhibition of HAdV
infection is determined by species-specific sequences in the virus
capsid and that critical neutralizing determinants are found in
both fiber and penton base; however, the lack of reduction in
overall HD5 binding to the resistant chimeric viruses suggests that
additional, non-neutralizing binding determinants remain intact.
Discussion
These studies extend our understanding of the mechanism of a-
defensin-mediated neutralization of HAdV. We observed species-
specific neutralization of HAdVs, which is dependent upon
defensin binding to the virus capsid. Thousands of defensin
molecules bind to each virus particle with an approximate KD that
correlates well with the IC50 for virus infection, and antiviral
activity is dependent upon the tertiary structure of a correctly
folded a-defensin molecule. Structural analysis by cryoEM
indicates that defensins bind to all of the exposed major capsid
proteins. Based on sequence analysis and cryoEM studies, we
proposed that potential critical sites for defensin binding are
located at the point of contact between penton base and fiber. The
importance of these sites for defensin neutralization was confirmed
by an analysis of virus chimeras comprised of sequences from
sensitive and resistant HAdV serotypes, indicating that neutrali-
zation determinants are found in both fiber and penton base. In
conjunction with our previous studies, this observation suggests a
model in which defensin binding to these critical neutralization
sites prevents fiber dissociation, thereby blocking subsequent steps
Figure 6. Neutralization determinants are located in fiber and penton base. A) Schematic of chimeric viruses. Capsid proteins are depicted
in the order in which they are encoded in the virus genome for HAdV-5 (white) and HAdV-19c (grey). The variable residues in fiber (GYAR and DTET)
are indicated for each construct. B) Each of the chimeric viruses was incubated with 5 mM (grey) or 10 mM (black) HD5 and assessed for infectivity on
A549 cells. Data are the mean of the percent infectivity compared to control cells infected with each virus in the absence of defensin for at least three
independent experiments 6 SD. The upper limit for quantification of this assay is 200%.
doi:10.1371/journal.ppat.1000959.g006
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endosomalysis, and infection.
Differential susceptibility to defensin was previously observed in
studies of cutaneous and genital serotypes of HPV [9], suggesting
that there are specific determinants on the HPV capsid that dictate
defensin neutralization. To investigate whether this is also the case
for HAdV, we tested the sensitivity of representative serotypes
from 6 of the 7 HAdV species to defensins HD5 and HNP1.
Consistent with more limited previous studies [12], we found that
sensitivity to defensins is species specific. Because the defensin-
capsid interaction is at least in part based on electrostatic
interactions [13], a simple hypothesis is that defensin sensitivity
would correlate with net hexon charge. However, this is not the
case, even though the major electrostatic property of the AdV is
from hexon [39]. This observation supports a model in which
specific binding determinants dictate defensin sensitivity.
This conclusion is bolstered by the observation that only
correctly folded HD5 has antiviral activity. Previous studies
showed that the chemokine activity of some defensins is dependent
upon defensin conformation [28]. a-defensin inhibition of
bacterial toxins is also significantly reduced in defensin derivatives
that cannot form disulfide bonds, as in the HD5-Abu used here
[29,40]. As HD5-Abu retains the same net positive charge as the
correctly folded HD5, a purely charge-dependent mechanism
cannot explain the neutralizing activity of this antimicrobial
peptide. Similarly, although all natural defensins have a net
positive charge, not all defensins (e.g., HBD-2) neutralize HAdV
infection [8,12,13]. Therefore, these studies support the hypothesis
that the HAdV capsid-defensin interaction is due to specific
recognition of the virus capsid by defensins.
We used an equilibrium-binding assay to measure the affinity
and stoichiometry of the defensin-capsid interaction. We found
that as many as 2750 HD5 molecules are bound to each virus
particle at saturation (Vmax) with an apparent affinity (KD) that
approximates the IC50 for infection. The use of surface plasmon
resonance to more accurately measure the capsid-defensin
interaction would have been preferable for these studies; however,
the large mass difference between HD5 (3.6 kDa) and the virus
particle (150 MDa) precludes this approach. Although our analysis
likely approximates the binding parameters of the system, there
are some limitations. First, it is semi-quantitative because of the
methods used to estimate both the number of virus particles in
each sample and the amount of defensin bound. Second, there is
no estimation of non-specific binding. Nonetheless, the data more
closely fits a specific binding curve.
Our binding studies suggest one possible explanation for the
enhancement of infectivity that is commonly observed for resistant
serotypes. We observe specific binding of HD5 to the sensitive
HAdV-5 and HAdV-7 serotypes but only a low level of binding to
the resistant HAdV-19c, -25p, and -51p. Therefore, both
neutralizing and non-neutralizing binding sites are likely present
on the capsid. Defensin binding to non-neutralizing sites may
neutralize electronegative surface charges and facilitate virus
binding to the cell surface, functionally analogous to the enhancing
effect of polybrene on retrovirus infection [41]. Consistent
with this hypothesis, we showed that receptor-dependent and
-independent binding of HAdV-5 to cells is enhanced by HD5, but
not HD5-Abu, despite a complete block of productive infection.
Moreover, mutation of critical neutralization determinants in the
19cF and PB/GYAR chimeras did not result in a noticeable
reduction in overall HD5 binding. Thus, the capsid-defensin
interaction is complex, and the presence or absence of critical
neutralization determinants dictates the outcome (inhibition or
enhancement).
The extensive difference density attributable to HD5 in our
cryoEM analysis of Ad5.F35+HD5 is consistent with our estimated
stoichiometry. HD5 binding sites were found on all of the major
proteins of the capsid. Our studies do not address a physiologic
role for hexon binding, although this binding may contribute to
enhancement of infection due to charge neutralization. The
accumulation of HD5 difference density was not equal among the
four unique hexon positions in the asymmetric unit but rather was
greatest on the peripentonal hexons. Since the possible binding
sites presented by each hexon are equivalent, this may be due to
multimerization of HD5 at the vertices, potentially creating
bridges between the peripentonal hexons and the penton base.
In crystal structures, a-defensins form dimers [42,43]; however, it
is unclear whether or not defensin dimerization plays a physiologic
role. HD5 has been shown to form dimers and tetramers at
concentrations below 5 mM, defensin self-association is greatly
enhanced by binding to target proteins, and mutations that disrupt
the ability of HD5 to form dimers also reduce target protein
binding [40,44]. Therefore, defensin dimerization or multimeriza-
tion may also contribute to AdV binding and antiviral activity.
Similarly, we observed extensive binding of HD5 to the fiber.
The fiber shaft was substantially thicker in the presence of HD5,
and the fiber knob was poorly reconstructed. Either HD5 induces
greater conformational flexibility in the fiber shaft leading to
greater averaging of the fiber knob density, or HD5 affects the
linker region between the shaft and the knob. Both the RGD loops
and the fiber shaft contain multiple negatively charged residues
that might serve as binding sites for the positively charged HD5
molecule. Nonetheless, the capacity of fiber to bind to CAR was
not compromised by HD5 binding based on our previous studies
showing HAdV-5 cell entry in the presence of HD5 and the
observed reduction in cell binding of HAdV-5/HD5 in compe-
tition with 5FK [13,36].
Our virus chimera studies support the existence of multiple
binding determinants in the penton complex that are critical for
neutralization. Disruption of a single binding determinant (e.g.
DTET in fiber) is insufficient to completely abrogate neutraliza-
tion. Rather, two or more sites must be simultaneously disrupted,
as in the PB/GYAR chimera, to generate defensin resistance.
Because resistance was also observed in the 19cF construct, at least
two separate determinants are likely found in fiber. In each case,
disruption of the neutralization sites led not only to resistance, but
also to enhancement of infection. This finding supports the notion
that enhancement and neutralization are competing processes
mediated by defensin binding. Analysis of additional virus
chimeras to map the neutralization determinants may provide a
more detailed description of the binding sites important for
inhibition and enhancement. They may also help explain the
resistance of HAdV-41 to HD5 despite the presence of one acidic
residue in the identified fiber neutralization determinant of both
the short and long HAdV-41 fibers.
Based on our combined functional and structural studies, we
propose a model for neutralization in which a-defensins bind to
critical capsid determinants at the point of contact between fiber
and penton base, thereby preventing fiber release. One implica-
tion of this model is that fiber dissociation is absolutely required for
subsequent uncoating events. This model cannot distinguish
between the dissociation of fiber and penton base from the capsid
independently or together as a complex. In the first case, defensin
may actively lock the fiber onto the penton base. Alternatively,
HD5 may obstruct a conformational change in penton base that is
required for its release with fiber still attached. Our studies provide
strong support for a mechanism of neutralization of HAdV-5 by
HD5 and, in combination with our previous report demonstrating
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suggest that other sensitive serotypes are neutralized by HD5 by a
similar mechanism. However, detailed studies of additional
HAdV/defensin combinations may reveal differences in the
mechanisms.
Although the temporal order of uncoating events suggests that
fiber release is a critical step [21,22], no previous example of a
specific inhibitor of this step leading to a block to infection has
been described. Therefore, our studies not only provide insight
into the mechanism of defensin-mediated neutralization of non-
enveloped virus infection but also provide a new rationale for the
design of entry inhibitors. In addition, our results shed further light
on the earliest events of HAdV disassembly occurring during cell
entry. Because other non-enveloped viruses (e.g., HPV) are also
inhibited by defensins, studies of defensin neutralization may also
provide insight into the entry mechanisms of these viruses.
The role of defensins in vivo against adenovirus or other non-
enveloped viruses has not been demonstrated; however, several
observations suggest that the neutralization model studied here
could be relevant for antiviral immunity. HD5 concentration in
the intestinal lumen has been estimated at 14–69 mM (50–250 mg/
ml) [45], which is greater than that required to neutralize HAdV
infection. Many HAdVs, including those that cause respiratory
infections, have been shown to infect and replicate in the bowel
and have been detected upon shedding in the feces. Thus, sensitive
HAdV serotypes may encounter HD5 secreted by Paneth cells
during natural infection. It is intriguing that HAdV-F serotypes,
which cause primarily gastrointestinal infections, are resistant to
HD5. The alpha-defensins of human neutrophils are found at high
concentration in azurophil granules [46,47]. Although measured
at low concentrations in plasma, these molecules can be secreted
or found in phagocytic vacuoles at high local concentrations
(.10 mg/ml) [47–49]. These cells home to the site of infection
where they could encounter HAdV in many tissues, including the
ocular, oral, and pulmonary mucosa. AdVs have also been shown
to interact directly with neutrophils and to be engulfed [50].
Additional studies are required to assess the role of defensins in
antiviral immunity in vivo.
Materials and Methods
Cells, viruses, and peptides
Tissue culture reagents were obtained from Invitrogen (Carls-
bad, CA). Human A549 cells (ATCC) were propagated in DMEM
supplemented with 10% FBS. Stable 293 cells over-expressing the
human b5 integrin subunit (293b5) were created by transfecting
293 cells (ATCC) with the human b5 gene (pCDNA3/b5, a gift
from David Cheresh, University of California, San Diego; San
Diego, CA). Transfected cells were selected for high integrin
expression. Stable 293 cells over-expressing the V-protein of the
paramyxovirus Simian virus 5 (293-SV5/V) were a gift of Kenneth
Mellits (University of Nottingham, Loughborough, UK) [51].
HAdV-2p, -3p, -4p, -11p, -12p, -25p, -35p, -37p, -41p, and -51p
were from ATCC. HAdV-7p and -14p were gifts of David
Metzgar (Naval Health Research Center, San Diego, CA). HAdV-
16p and -23p were gifts of Adriana Kajon (Lovelace Respiratory
Research Institute, Albuquerque, NM). HAdV-19c was a gift of
James Chodosh (Harvard Medical School, Boston, MA) [52]. The
replication-defective HAdV-5 vector used in these studies
(Ad5.eGFP) is E1/E3-deleted and contains a CMV promoter-
driven enhanced green fluorescent protein (eGFP) reporter gene
cassette. Ad5.F35 was constructed by replacing the entire fiber
gene from a HAdV-5-based vector expressing b-galactosidase with
that of HAdV-35p [53].
Virus chimeras were created by replacing the entire open
reading frames of the HAdV-5 penton base or fiber with that of
HAdV-19c by recombineering [54] in a BAC construct (pAd5-
GFPn1) containing the entire genome of an E1/E3-deleted
HAdV-5 vector expressing eGFP [55]. The GYAR and PB/
GYAR constructs were created by replacing the codons for DTET
in the HAdV-5 fiber gene with those for GYAR from HAdV-19c
in the original pAd5-GFPn1 plasmid or in the previously
constructed PB chimera plasmid, respectively. The fidelity of the
chimera constructs was verified by sequencing the recombineered
region and by restriction digest. To generate virus, 293b5 cells
were transfected with the large Pac I restriction fragment of these
BACs. Transfected cells were cultured until visible plaques formed.
The identity of the final virus stock was confirmed by restriction
digest. PCR was used to verify purity and absence of cross-
contamination. The GYAR substitution in the fiber protein was
confirmed by sequencing a PCR product from the final virus stock.
All wild type viruses were propagated in 293b5 or A549 cells
except for HAdV-41p, which was propagated in 293-SV5/V. All
AdV vectors were propagated in 293b5 cells. Cultures were
infected with 300 particles/cell of purified viruses or from cleared
lysates of original virus stocks. When complete cytopathic effect
was observed, cells were harvested and concentrated by low speed
centrifugation. For some serotypes, virus was precipitated from
supernatant using 8% PEG [56]. Cell pellets were disrupted by
three cycles of freezing and thawing. Mature virus was purified
from the cleared lysate or PEG precipitate by two consecutive
rounds of centrifugation [2–3 h at 111,0006g (avg.)] through
continuous 15% to 40% CsCl gradients, dialyzed against three
changes of A195 buffer [57], flash frozen in liquid nitrogen, and
stored at 280uC.
Synthetic HNP1, HBD2, and HD5 were obtained from
Peptides International, Inc. (Louisville, KY). HD5 derivatives
containing the E14Q substitution or L-a-aminobutyric acid in
place of cysteine were produced by solid phase chemical synthesis
as described [25,58]. The ribbon representation of HD5 (PDB
1ZMP) was generated with PyMOL [59]
Infection assay
Prior to use in this assay, each virus stock was titrated on A549
cells. A virus concentration was chosen to produce 50–70%
maximal signal in the absence of defensin as described below. To
measure the effect of defensins on infectivity, purified virus was
incubated with HD5 or HNP1 for 1 h on ice in serum-free
DMEM (SFM). Confluent A549 cells in black wall, clear bottom
96-well plates were washed twice with SFM, and virus/defensin
mixtures were added in a final volume of 35 ml/well. In parallel,
wells were infected with two-fold serial dilutions of each virus to
establish a standard curve for quantification with an upper limit of
200%. After 2 h, wells were washed twice and replaced with
DMEM/10% FBS. Samples were incubated for approximately
48 h, fixed with paraformaldehyde, permeabilized in 20 mM
glycine/0.5% Triton X-100 in PBS, and stained with an anti-
hexon primary antibody (8C4, Fitzgerald Industries International,
Acton, MA) and an Alexa Fluor 488-conjugated anti-mouse
secondary antibody (Invitrogen, Carlsbad, CA). Plates were
scanned for Alexa Fluor 488 signal using a Typhoon Trio variable
mode imager (GE Healthcare, Piscataway, NJ). Total well
fluorescence above background was quantified with ImageJ
software [60]. For each virus, samples were quantified by
nonlinear regression against the standard curve using Prism
software (GraphPad Software, Inc., La Jolla, CA).
To test the activity of HD5 derivates, Ad5.eGFP was incubated
with 15 mM of HD5, HD5-Abu, or HD5-E14Q. Infectivity was
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described [13].
Virus-defensin binding assay
T om e a s u r eH D 5b i n d i n gt oH A d V - 5a n d- 5 1 ,H D 5w a ss e r i a l l y
diluted in PBS and mixed with 5 mg purified virus. After 1 h
incubation on ice, one half of each sample was separated by
ultracentrifugation [209,0006g (avg.) for 2 hrs at 4uC] on a
discontinuous gradient consisting of 300 ml of 30% nycodenz and
200 ml of 80% nycodenz in 50 mM NaCl, 20 mM HEPES pH 7.4
using an SW55ti rotor with adaptors (Beckman Coulter, Inc.). The
visible virus band was collected. The other half of each sample was
used to make a standard curve for quantification. All samples were
boiled in reducing loading buffer and separated using a 16%
PAGEgel (Expedeon, Inc., San Diego, CA) or 10–20% Tris-Tricine
gel (Bio-Rad, Hercules, CA). The gels were stained with Deep Purple
(GE Healthcare) and imaged on a Typhoon Trio. Virus bands were
quantified using ImageQuant NT software (GE Healthcare). The
amount of HD5 in each sample was normalized to protein V and
hexon. The amount of HD5 in the centrifuged samples was then
quantified against the standard curve using Prism software. Affinity
and stoichiometry were estimated from the average data of at least
three independent experiments using Prism software.
Fiber knob competition assay
Recombinant HAdV-5 fiber knob (5FK) comprising residues 387–
581 of the HAdV-5 fiber and HAdV-16 fiber knob (16FK)
comprising residues 151–353 of the HAdV-16 fiber, each containing
an N-terminal hexahistidine tag, were expressed in BL21(DE3) cells
(Invitrogen, Carlsbad, CA) and purified using TALONMetal Affinity
Resin (Clontech, Palo Alto, CA) as previously described [61,62].
Alexa Fluor 448 labeled-Ad5.eGFP [13] (4.2610
9 particles/sample)
was incubated with or without 20 mM HD5 or HD5-Abu for 45 min
on ice. In parallel, 1610
5 A549 cells in PBS+0.2% sodium azide were
incubated with or without 200 nM 5FK or 16FK for 45 min on ice.
The virus/defensin mixtures were combined with the cell/FK
mixtures (final volume 100 ml/sample) and incubated for 45 min on
ice. Samples were washed 2 times with cold PBS+1% FBS, fixed with
1% paraformaldehyde, and analyzed by flow cytometry for Alexa
Fluor 488.
CryoEM and image processing
Purified Ad5.F35 (160 mg/ml) was combined with HD5
(20 mM) and incubated for 45 min on ice. CryoEM grids were
produced with an FEI Vitrobot. Electron micrographs were
collected on an FEI Polara microscope (300 kV, FEG) operated at
300kV with the grids at liquid nitrogen temperature using the
SAM semi-automatic data collection routine [63]. The defocus
values of the micrographs ranged from 0.5 mmt o4 mm. The
absolute magnification of the digital micrographs collected on a
Gatan UltraScan 4000 (400064000 pixel) CCD camera was
397,8786, corresponding to a pixel size of 0.4 A ˚ on the molecular
scale. Individual particle images were selected from micrographs
with in-house scripts and computationally binned to produce
particle image stacks with various pixel sizes suitable for image
processing (4.8 A ˚, 2.4 A ˚, and 1.6 A ˚). Particle images with a pixel
size of 4.8 A ˚ were used for initial CTF parameter determination
with CTFFIND3 [64] and orientational parameter determination
with FREALIGN [65]. A cryoEM structure of Ad5.F35 [31] was
used as the starting three-dimensional model for FREALIGN
refinement. Intermediate refinement rounds were performed using
particle images with a 2.4 A ˚ pixel and the final rounds of
refinement were performed using particle images with a 1.6 A ˚
pixel. Magnification refinement for the previously acquired
Ad5.F35 and the new Ad5.F35+HD5 cryoEM particle images
was performed together on a per particle basis in FREALIGN.
Separate three-dimensional structures were generated for Ad5.F35
and for Ad5.F35+HD5 based on 3,040 and 2,611 particle images,
respectively. The pixel size of the final structures was determined
to be 1.61 A ˚ by optimizing the agreement between the docked
HAdV-5 hexon crystal structure (PDB 1P30) [32] and the cryoEM
density maps with UCSF Chimera [66]. The resolution of the
icosahedral capsid (radii 300–463 A ˚) of the Ad5.F35 reconstruc-
tion estimated by Fourier shell correlation is within the range of
6.9–5.3 A ˚; 6.9 A ˚ (FSC 0.5 threshold); 6.1 A ˚ (FSC 0.3); and 5.3 A ˚
(FSC 0.143). The resolution of the icosahedral capsid of the
Ad5.F35+HD5 reconstruction is 12.3–8.2 A ˚; 12.3 A ˚ (FSC 0.5
threshold); 10.9 A ˚ (FSC 0.3); and 8.2 A ˚ (FSC 0.143). Both the
Ad5.F35 and Ad5.F35+HD5 reconstructions were sharpened with
a temperature factor of B=2450 A ˚ 2 and filtered to 12 A ˚
resolution with cosine edge filtering using the BFACTOR
program (http://emlab.rose2.brandeis.edu/software).
Difference mapping was performed by docking the HAdV-5
hexon (PDB 1P30) and HAdV-2 penton base/fiber N-terminal
peptide crystal structure coordinates (1X9T) [33] within one facet
of each reconstruction. The docked coordinates were converted to
a density map with the pdb2mrc routine of EMAN v1.7 [67],
filtered to 12 A ˚ resolution, normalized, and subtracted from the
Ad5.F35 and Ad5.F35+HD5 reconstructions.
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